Compare Illumina, Inc. (ILMN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Vanguard Short Term Corporate Bond ETF trades at $78.58. The key difference: Illumina, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | VCSH | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Fixed Income |
52-Week High | $194.33 | $80.20 |
52-Week Low | $91.00 | $78.45 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
VCSH trades at $78.64, down 0.1% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a steady dividend payout, with recent distributions of $0.29-$0.30 per share. News highlights institutional activity, including Allspring Global Investments purchasing 1.47 million shares in July 2026. The fund's focus on short-term corporate bonds offers a higher yield compared to treasury alternatives, though it carries greater credit risk.
The outlook for VCSH is mixed, balancing income appeal against interest rate sensitivity. Opportunities include attractive yield and low expense ratio, while risks involve Fed policy uncertainty and credit spread volatility. Investors seeking short-duration corporate exposure may find value, but should monitor rate expectations and economic conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
